SDCBP Orchestrated Gastric Cancer Aggression Through Epithelial‐ Mesenchymal Transition and Macrophages M2 Polarization
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.23923 ↗At a glance
Journal article in Molecular Carcinogenesis, 2025. Written by Chan-Yuan Zhao and 14 co-authors. Institution: Institute of Pathology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China. Major MEDLINE topics: Stomach Neoplasms, Epithelial-Mesenchymal Transition, Macrophages, Syntenins. Cited 1 times so far (Crossref); 38 references. Funded by: This work was supported by the National Natural Science Foundation of China (Nos. 81672399 and 81871919), Natural Science Foundation of Gansu Province (Nos. 22…, Natural Science Foundation of Gansu Province.
Topics: Gewalt gegen Pflegekräfte
Abstract (original language)
Gastric cancer remains a significant global health burden with limited treatment options and high mortality. Syndecan‐binding protein (SDCBP), a scaffolding protein involved in tumor differentiation, has attracted attention as a potential therapeutic target in cancers. However, its precise role in gastric cancer progression is not fully understood. In this study, through bioinformatics analysis and gastric cancer samples detection, we discovered that SDCBP was highly expressed in gastric cancer tissues, which was correlated with clinicopathological features such as tumor invasion depth and distant metastasis, and exhibited heterogeneity across histological or molecular subtypes. Elevated SDCBP expression promoted the proliferation, invasion and migration of gastric cancer cells, and modulated epithelial‐mesenchymal transition (EMT) via the ERK signaling pathway. Xenograft experiments in mice confirmed that inhibiting SDCBP or ERK signaling could delay cancer progression. We also found that gastric cancer cells with SDCBP knockdown were able to inhibit the M2 polarization of cocultured macrophages, reduce chemotaxis and enhance phagocytosis of macrophages. Therefore, SDCBP plays a crucial role in driving gastric cancer progression. Targeting SDCBP in gastric cancer can partially reverse the malignant phenotype, and SDCBP is expected to be a promising therapeutic target for gastric cancer.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Pathology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
- The Forensic Identification Unit of Lanzhou University, Lanzhou, China.
- Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University, Lanzhou, China.
- Gansu Provincial Maternity and Child-care Hospital/Gansu Provincial Central Hospital, Lanzhou, China.
- Medical College of Northwest Minzu University, Lanzhou, China.
- Experimental Teaching Center of Basic Medicine, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
ORCID profiles: Min Li
Funding
- This work was supported by the National Natural Science Foundation of China (Nos. 81672399 and 81871919), Natural Science Foundation of Gansu Province (Nos. 22…
- Natural Science Foundation of Gansu Province
Cite
APA
Zhao, C. Y., Liu, F., Dong, J. M., Du, C. P., Zhang, C. L., Wang, C. Y., Zhang, X. Y., Zhou, Q., Liu, W., Yang, A. J., Zhou, Y. N., Dang, Y., Shang, L. N., Wang, M., & Li, M. (2025). SDCBP Orchestrated Gastric Cancer Aggression Through Epithelial‐ Mesenchymal Transition and Macrophages M2 Polarization. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23923
Vancouver
Zhao CY, Liu F, Dong JM, Du CP, Zhang CL, Wang CY, et al. SDCBP Orchestrated Gastric Cancer Aggression Through Epithelial‐ Mesenchymal Transition and Macrophages M2 Polarization. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23923
BibTeX
@article{Zhao2025,
author = {Zhao, Chan-Yuan and Liu, Feng and Dong, Jia-Ming and Du, Cun-Pu and Zhang, Chen-Li and Wang, Chen-Yu and Zhang, Xiao-Yu and Zhou, Quan and Liu, Wei and Yang, Ai-Jun and Zhou, Yong-Ning and Dang, Yun and Shang, Li-Na and Wang, Min and Li, Min},
title = {SDCBP Orchestrated Gastric Cancer Aggression Through Epithelial‐ Mesenchymal Transition and Macrophages M2 Polarization},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.23923}
}
EUVIMED